Recombinant Covid-19 vaccine (Recbio)

近日，瑞科生物与易康生物（苏州）有限公司（“易康生物”）签订产品开发合作协议（“该协议”），共同开发重组呼吸道合胞病毒（RSV）疫苗，用以预防由RSV引起的呼吸道疾病。该协议表明瑞科生物的核心佐剂技术可以赋能产业链合作伙伴，易康生物基于独特的结构生物学技术设计改良的疫苗抗原具有显著优势，后续更多合作值得期待。 根据该协议条款，易康生物将提供其自主设计的RSV抗原，瑞科生物将提供其自主开发的新型佐剂，双方联合开展重组RSV疫苗的开发。 RSV是一种极为普遍且具有传染性的病毒，可导致儿童、老年人及免疫功能受损者出现潜在的严重呼吸道疾病。因年龄增大和免疫力下降，老年人罹患重度RSV疾病的风险很高。目前，我国尚无专门针对RSV的预防性疫苗上市销售。据统计，2022年全球65岁及以上老年人RSV严重感染发病人数为860万人，中国为220万人。且RSV感染是引起全球幼儿下呼吸道感染的首要诱因。 “RSV疫苗是开发前景非常明确的重大传染病疫苗，也是国际创新疫苗竞争的新焦点。抗原设计是RSV疫苗成功的基础，佐剂是产品竞争力的关键。易康团队在疫苗抗原设计领域，瑞科团队在新型佐剂研发、产业化应用领域都处于领先水平。”瑞科生物创始人、董事会主席兼总经理刘勇博士表示，“瑞科生物愿意提供最佳佐剂技术和疫苗注册、临床、产业化资源，与易康生物携手共同推动国产RSV疫苗早日进入临床，早日上市。希望以此为契机推进双方更广泛深入的合作。” 关于易康生物 易康生物成立于2017年，公司专注于以蛋白质三维结构为基础和逆向疫苗研发理念为核心，采用蛋白质晶体X射线衍射和冷冻电镜的方法解析生物大分子的三维结构，发现病毒躲避免疫系统的生物学机制及弱点，使用已经建成的蛋白质结构生物学研发平台创新开发多种人类及动物病毒性传染病重组蛋白疫苗及中和抗体药物，获得了多项疫苗和抗体药物发明专利。在结构生物学基础上设计改良的重组蛋白疫苗具有安全、稳定、精准、高效、广谱和生产成本低的优势。公司致力于创制安全高效优质的疫苗和抗体药物，改善人们的生活品质，使人们生活得更加舒适长久！ 关于瑞科生物 江苏瑞科生物技术股份有限公司(股票代码：02179.HK) 始创于2012年，是一家以自主研发技术为核心驱动力的创新型疫苗公司，致力于打造覆盖研发、生产及商业化的创新型疫苗。长期以来，公司始终秉持“创制一流疫苗，守护人类健康”的使命，凭借由新型佐剂、蛋白工程、免疫评价、mRNA疫苗等核心技术平台组成的强大研发引擎，公司已建立由10余款高度差异化组成的高价值创新型疫苗组合，覆盖宫颈癌、带状疱疹、新冠肺炎等具有重大负担的疾病领域。核心产品重组HPV九价疫苗REC603，目前正处于III期临床试验阶段，临床进度领先。此外，重组新冠病毒疫苗ReCOV已成为全球最具竞争力的第二代新冠疫苗之一，其免疫原性全面优效于辉瑞mRNA疫苗。新佐剂重组带状疱疹疫苗REC610具有较好的免疫原性，其表现非劣于国际主流的Shingrix疫苗，目前已进入临床阶段。瑞科生物已制定明确清晰的商业化策略，旨在于全球范围内进一步渗透多元化疫苗市场。十年磨剑，厚积薄发，瑞科生物即将进入产品商业化的爆发期。 内容来源于网络，如有侵权，请联系删除。

TAIZHOU, China, Aug. 27, 2023 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and interim results for 2023. During the reporting period, the company always adhered to the mission of " Protect Human Health With Best-In-Class Vaccines", rapidly promoted product research and development, and achieved the following milestones and progress in research pipeline and business operations. Follow-up on the subjects of REC603's primary efficacy trial is being conducted in accordance with the clinical protocol. We have completed the 18th month follow-up visit and are conducting the 24th month follow-up visit observation.The Phase III clinical program is highly consistent with the guiding principles of the regulatory authorities, the sample size and the clinical site advantages are obvious.Currently, the Company is conducting follow-up visits according to the established protocol and is expected to accelerate the completion of case collection, maintaining the leading domestic position in the clinical development progress The application for Chinese clinical trial of novel adjuvanted recombinant shingles vaccine REC610 has been officially accepted. Overseas phase I clinical progress is smooth, the overall safety and tolerability is good We continuously strengthen the construction of independent intellectual property rights for innovative vaccines.We have applied for a number of invention patents related to respiratory syncytial virus vaccine (RSV),new novel adjuvants and other projects. Cash and cash equivalents were approximately RMB 1.099 billion as of June 30, 2023, compared to RMB 1.325 billion as of December 31, 2022 Operating expenses (R&D and administrative expenses) for the first half of 2023 were approximately RMB 326 million .Compared to the first half of 2022, the reduction was approximately 24.41% The loss during the period was approximately RMB 277 million, narrowed by 22.4% year-on-year BUSSINESS HIGHLIGHTS REC603-Recombinant HPV 9-valent Vaccine HPV 9-valent vaccines can provide protection against 90% of cervical cancer and 90% of the anal and genital warts, being widely considered as the most effective vaccines against HPV-related diseases. Currently, no domestic HPV 9-valent vaccine has been approved for marketing in China. We are in the process of conducting phase III clinical trial in China. The phase III clinical trial in China consists of three parts, i.e., the primary efficacy trial, the immuno-bridging trial in younger-age groups, and the immunogenicity comparative trial with Gardasil®9, with a multi-center, randomized, blinded and placebo controlled design and with a total size of 16,050 subjects. Follow-up on the subjects of REC603's primary efficacy trial is being conducted in accordance with the clinical protocol. We have completed the 18th month follow-up visit and are conducting the 24th month follow-up visit observation. We plan to take the pathological endpoint for interim analysis and submit BLA application to the NMPA for REC603 after meeting the conditions. The Company has completed the three doses vaccination in the two studies of REC603 immuno-bridging trial in the younger-age groups and the immunogenicity comparative trial with Gardasil®9. The "Technical Guidelines for the Clinical Trials of Human Papillomavirus Vaccines (for Trial Implementation)" issued by the Center for Drug Evaluation of NMPA clearly states that "randomized, double-blind, placebo-controlled design is currently the best strategy to confirm the protective efficacy of first-generation vaccines." Our Phase III clinical protocol for the 9-valent HPV vaccine strictly follows the guidelines of the regulatory authorities; We have the largest HPV 9-valent Phase III clinical trial subjects in China and are conducting clinical trials in Henan, Shanxi and Yunnan provinces with high HPV infection rates. Currently, the Company is conducting follow-up visits according to the established protocol and is expected to accelerate the completion of case collection, maintaining the leading domestic position in the clinical development progress. REC610 – Novel Adjuvanted Recombinant Shingles Vaccine Shingles is an acute infectious skin disease caused by reactivation of latent varicella zoster virus (VZV) in the body. There is no specific medicine for shingles, and vaccine is an effective means of preventing shingles. According to research data on shingles vaccines that have been marketed around the world, the novel adjuvanted vaccine can provide stronger cellular immunity and protective efficacy as compared to live attenuated vaccines. The Company has recently received the notice of acceptance (acceptance number: CXSL2300518) issued by NMPA, pursuant to which the clinical trial application for its self-developed novel adjuvanted recombinant shingles vaccine REC610 has been accepted. The Company proposes to adopt a randomized, double-blind, Shingrix® parallel controlled phase I clinical trial in 180 healthy adult subjects aged 40 and above in Mainland China to evaluate the safety, tolerability of REC610 and have a preliminary assessment of its immunogenicity. The Company commenced the first-in-human GSK Shingrix® active controlled clinical trial of REC610 in the Philippines in February 2023. Currently, the clinical trial is being executed smoothly. All subjects have completed 30 days of follow-up studies after two doses of the vaccination, with favorable safety and tolerability profile. REC610 is equipped with a novel adjuvant BFA01 independently developed by the Company, which can promote the production of high levels of VZV glycoprotein E (gE)-specific CD4+T cells and antibody. Preclinical studies have shown that REC610 has favorable immunogenicity and can induce high levels of gE specific CD4+T cell responses and IgG antibody, and its immune response is non-inferior to the controlled vaccine Shingrix®. ReCOV-Recombinant COVID-19 Vaccine ReCOV is a recombinant COVID-19 vaccine being developed by the Company with its technology platforms, including its novel adjuvant, protein engineering and immunological evaluation platforms, and the adjuvant used therein is its self-developed novel adjuvant BFA03. It has a variety of comprehensive advantages, including favorable broad-spectrum of neutralizing antibodies and immune persistence, overall positive safety profile, potential growth in production scale, low production cost, preparation stability, and ability to be stored and transported at room temperature. For ReCOV international multi-center Phase III clinical trial, we have completed all subjects enrollment and full vaccination, and is currently under follow-up visit in accordance with the clinical protocol. We will analyze the endpoint of protective efficacy, and submit the application to the PRC regulatory authorities after meeting the conditions. We obtained an emergency use authorization (EUA) for ReCOV in Mongolia in March 2023. Others We continuously strengthen the construction of independent intellectual property rights for innovative vaccines. Based on the protein engineering platform and mRNA technology platform, we have applied for a total of 15 invention patents related to antigens for respiratory syncytial virus vaccine (RSV),recombinant human herpes simplex virus vaccine (HSV), SARS-COV-2 and its variants projects. Based on the novel adjuvant platform, we applied for a total of 16 invention patents in the key raw materials of adjuvants, among which 1 novel adjuvant authorized patent was obtained. In April 2023, the Company received the Reply of the Approval on the Registration of Shares Issued by Jiangsu Recbio Technology Co., Ltd. to Target Subscribers from the CSRC. The Reply should be valid for a period of 12 months from the date of approval. In May 2023, the Company has been selected as a constituent of the MSCI China Small Cap Index, with effect from the close of market on May 31, 2023. FINANCIAL HIGHLIGHTS Cash and bank balances Cash and cash equivalents were approximately RMB 1.099 billion as of June 30, 2023, compared to RMB 1.325 billion as of December 31, 2022. R&D and administrative expenses Operating expenses (R&D and administrative expenses) for the first half of 2023 were RMB 326 million .Compared to the first half of 2022, the reduction was approximately 24.41%. About Recbio Founded in 2012, Jiangsu Recbio Technology Co., Ltd. (hereinafter referred to as Recbio or the Company; stock code: 02179.HK) is an innovative vaccine company driven by self-developed technologies. We are dedicated to the R&D, production and commercialization of innovative vaccines, leveraging our core technology platforms (novel adjuvant, protein engineering, immunological evaluation). Staying true to the mission of "Protect human health with best-in-class vaccines", the Company has established high-value pipelines consisting of several blockbuster vaccines with proprietary rights to satisfy the huge unmet demands in the markets of high-burden diseases. Through years of devotion to the vaccine industry, Recbio has developed three advanced innovative technology platforms, namely novel adjuvant, protein engineering and immunological evaluation platforms, and become one of the few companies in the world capable of developing novel adjuvant systems. We develop promising vaccine candidates constantly, taking advantage of the synergy between the novel adjuvant platform, optimized antigen designs, and immunological evaluation technologies. Recbio never ceases to optimize its technology platforms, and strives to achieve breakthroughs in mRNA vaccines using a joint venture model. With robust R&D capacity, the Company has developed high-value innovative vaccine portfolios consisting of ten-odd differentiated vaccines, covering cervical cancer, shingles, COVID-19, TB and other high-burden diseases. Our core product REC603, a recombinant 9-valent HPV vaccine in Phase III clinical trial, shows great promise of becoming the first marketed domestic 9-valent HPV vaccine. Apart from that, ReCOV, a recombinant COVID-19 vaccine with its commercialization in the offing, has been recognized as one of the most competitive next-generation COVID-19 vaccines in the world. Recbio has a clear commercialization strategy aiming to penetrate the diversified global vaccine market. Honed and refined for ten years, Recbio is going to reap the rewards as several products are approaching commercialization. For more information, please visit . Forward-looking statements This Press Release may contain projections, estimates, forecasts, targets, opinions, prospects, results, returns and forward-looking statements with respect to the financial condition, results of operations, capital position, strategy and business of the Group which can be identified by the use of forward-looking terminology such as "may", "will", "should", "expect", "anticipate", "project", "plan", "estimate", "seek", "intend", "target", "believe", "potential" and "reasonably possible" or the negatives thereof or other variations thereon or comparable terminology (collectively, "forward-looking statements"), including the strategic priorities, research and development projects, and any financial, investment and capital targets and any other targets, commitments and ambitions described in writing or verbally herein. Any such forward-looking statements are not a reliable indicator of future performance, as they may involve significant stated or implied assumptions and subjective judgements which may or may not prove to be correct, accurate or complete. There can be no assurance that any of the matters set out in the forward-looking statements are attainable, will actually occur or will be realised or are complete or accurate. The assumptions and judgments may prove to be incorrect, inaccurate or incomplete, and involve known and unknown risks, uncertainties, contingencies and other important actors, many of which are outside the control of the Group. There is also no assurance that the Group may develop or market its core products or other pipeline candidates successfully. Actual achievements, results, performance or other future events or conditions may differ materially from those stated, implied and/or reflected in any forward-looking statements due to a variety of risks, uncertainties and other factors (including without limitation general market conditions, regulatory changes, geopolitical tensions or data limitations and changes). Any such forward-looking statements are based on the beliefs, expectations and opinions of the Group at the date the statements are made, and the Group does not assume, and hereby disclaims, any obligation or duty to update, revise or supplement them if circumstances or management's beliefs, expectations or opinions should change. For these reasons, you should not place reliance on, and are expressly cautioned about relying on, any forward-looking statements. No representations or warranties, expressed or implied, are given by or on behalf of the Group as to the achievement or reasonableness of any projections, estimates, forecasts, targets, commitments, prospects or returns contained herein. Please refer to the announcements published by the Company on the websites of The Stock Exchange of Hong Kong Limited () or of the Company () for further details. If there is any inconsistency between this Presentation and the announcements, the announcements shall prevail. Jiangsu Recbio Technology Co., Ltd. Investor Inquiry: Email: [email protected] Tel: +86-0523-86818860 Media Inquiry: Email: [email protected] Tel: +86-0523-86818860